AI Test Pinpoints More Cancers Targeted by Astra, Glaxo Drugs
This article is for subscribers only.
Using artificial intelligence to pinpoint tumor cells with reduced ability to repair their own DNA can help identify tens of thousands of patients who would benefit from treatment with drugs from AstraZeneca Plc and GlaxoSmithKline Plc, researchers said.
Analyzing genetic tests with a machine-learning algorithm helps target cancers that are vulnerable to treatment with drugs called PARP inhibitors, according to a study from scientists at Harvard Medical School in Boston and the U.K.’s University of Cambridge.